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Abstract
Background: Polymorphisms in GSTT1, GSTM1 and GSTP1 impact detoxification of carcinogens
by GSTs and have been reported to increase susceptibility to environmentally related health
outcomes. Individual factors in arsenic biotransformation may influence disease susceptibility. GST
activity is involved in the metabolism of endogenous and exogenous compounds, including
catalyzing the formation of arsenic-GSH conjugates.
Methods: We investigated whether polymorphisms in GSTT1, GSTP1 and GSTM1 were associated
with risk of skin lesions and whether these polymorphisms modify the relationship between
drinking water arsenic exposure and skin lesions in a case control study of 1200 subjects frequency
matched on age and gender in community clinics in Pabna, Bangladesh in 2001–2002.
Results and discussion: GSTT1 homozygous wildtype status was associated with increased odds
of skin lesions compared to the null status (OR1.56 95% CI 1.10–2.19). The GSTP1 GG
polymorphism was associated with greater odds of skin lesions compared to GSTP1 AA, (OR 1.86
(95%CI 1.15–3.00). No evidence of effect modification by GSTT1, GSTM1 or GSTP1 polymorphisms
on the association between arsenic exposure and skin lesions was detected.
Conclusion: GSTT1 wildtype and GSTP1 GG are associated with increased risk of skin lesions.
Background
Arsenic exposure through drinking water is a global prob-
lem, and has reached crisis status in Bangladesh [1-5]. A
well established exposure-response relationship exists
between arsenic level of drinking water and skin
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lesions[6,7]. Skin lesions are considered one of the most
distinctive endpoints of chronic arsenic exposure[8].
It has been proposed that there are differences in suscep-
tibility to arsenic due to individual genetic variability in
biotransformation of the metal[9]. Polymorphisms in
GST genes have been associated with susceptibility to a
range of diseases, and GST polymorphisms alone and in
concert with environmental exposures are associated with
disease outcomes and behavior of several enzymes [10-
12]. Glutathione S-transferases (GST) are a superfamily of
enzymes that are key in the detoxification step of Phase II
metabolism, usually by catalyzing the conjugation of
reduced glutathione (GSH) into hydrophobic and elec-
trophilic compounds along with other Phase II enzymes
[10-12]. In vivo studies have shown that GSH serves as a
reducing agent required for the reduction of arsenate to
arsenite[13]. GSH also serves as a reducing agent in the
methylation of arsenic from arsenite to MMM (V) and
from MMA (III) to DMA (V) [13]. GST activity is involved
in the metabolism of endogenous and exogenous com-
pounds, including catalyzing the formation of arsenic-
GSH conjugates[13,14]. Animal data had demonstrated
that these conjugates are transported by multidrug resist-
ant protein transporters (MRP) from the liver to the bile
[14-17]. Glutathione and related enzymes are also
involved in cellular protection against reactive oxygen
species (ROS) [11,12]. Chronic arsenic exposure has been
shown to alter glutathione metabolism and cellular redox
status and maintenance of cellular redox state may have
an important role in arsenic related pathology[14,18,19].
The biologic control of GST enzymes is multifaceted in
that they demonstrate specific patterns of expression that
depend on sex, age, tissue, and species and vary between
individuals [11,20]. GSTM1, GSTT1 and GSTP1 are mem-
bers of the Mu (μ), Theta (θ), and Pi (π) classes respec-
tively[10]. Polymorphisms in GSTT1, GSTM1 and GSTP1
alone or in concert with environmental exposures may be
associated with increased susceptibility to environmen-
tally related diseases such as cancer and other clinical out-
comes[10,12]. The GSTT1 null and GSTM1 null genotypes
are deletion polymorphisms and have no θ or μ-glutath-
ione S transferase activity respectively. The GSTP1 poly-
morphism is a single base pair substitution where adenine
is replaced by guanine resulting in an amino acid change
in which isoleucine (I105) is replaced by valine (V105), pos-
sibly resulting in lower enzyme activity[21,22]. At higher
arsenic exposure, increased GST activity may be associated
with saturation of MRP transporters allowing increased
tissue accumulation[14]. We hypothesized that elevated
glutathione-S-transferase activity, specifically activity of
glutathione-μ,θ, and π transferases, may be associated
with increased risk of skin lesions.
We investigated the relationship between GSTT1, GSTM1,
and GSTP1 polymorphisms and skin lesions. In addition,
we assessed possible effect-modification by GST  geno-
types in modifying the risk of arsenic related skin lesions




This study was conducted in the Pabna district of Bangla-
desh, located north of Dhaka on the Pabna (Ganges)
River. Pabna was chosen for the following reasons: ele-
vated arsenic was suspected in some of the region's vil-
lages due to proximity to the River; Dhaka Community
Hospital (DCH) has a well established clinic network in
the area; and Pabna is representative of socioeconomic
status of much of non-urban Bangladesh. Eligible cases
were Pabna residents, at least 16 years of age, with one or
more type of skin lesion: diffuse/spotted melanosis, dif-
fuse/spotted keratosis, hyperkeratosis, or leukomelanosis.
One physician made the diagnosis, and treatment was
provided at DCH when necessary. Controls were healthy
individuals diagnosed as free of skin lesions and arsenic
related disease randomly selected in a 1:1 ratio from
Pabna, age of at least 16 years, living in the same village as
cases but not sharing a tube well. Controls were also fre-
quency matched to cases based on gender and age (+/- 3
years). To ensure heterogeneity of exposure and to prevent
overmatching on exposure, controls were further selected
so as to ensure that 80% were in "low-exposure" arsenic
(<50 μg/l) communities and 20% were from suspected
"high exposure" (≥50 μg/l) areas. This last ensured that
the exposure distribution among controls matched that
which has been reported for the Pabna region as a
whole[23].
Initial measurements of well arsenic levels were made
with Merck field test kits[24]. Individuals found to have
arsenic exposure greater than 50 μg/l were advised of alter-
native drinking water sources. The participation rate was
98.0%; a total of 24 subjects from 1224 declined to partic-
ipate. Cases and controls had similar reasons for refusal.
The population is ethnically homogenous, and similar to
the population of Bangla (West Bengal), India. Informed
consent was obtained from all study participants. The
study protocol was approved by the Institutional Review
Boards at Dhaka Community Hospital, Bangladesh and
Harvard School of Public Health Boston, MA, USA.
Interviews and sample collection
In 2001–2002, 1200 subjects were recruited. Physicians,
blinded to exposure status, examined potential cases and
controls. Trained interviewers administered the question-
naire regarding exposure, lifestyle factors, and collected
individual well water samples. Data were collected on lit-Environmental Health 2007, 6:5 http://www.ehjournal.net/content/6/1/5
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ers of water/liquid ingested per day, disease history, resi-
dential history including identification of the primary
water source (tube well), years of use, and use of a previ-
ous tube well.
Collection of well water samples was designed to mini-
mize bias. Due to the fact that "high" exposure (≥50 μgAs/
l) wells were often painted red and "low" exposure wells
(<50  μgAs/l) were often painted green, the field team
would have known if they had some indication as to
whether the well was above or below 50 μg As/l. However,
the field team did not know the arsenic concentration of
the well at the time the subject was examined and inter-
viewed, a procedure similar to a study in West Bengal [25].
Additionally, it has been documented that wells are often
mislabeled[26]. Thus, the field team was blind to the true
exposure level of the subjects at the time case status was
determined. Water samples were analyzed in the United
States and the field team received results after subjects
were enrolled.
Upon collection of each 100 ml water sample two drops
(0.2 ml) of pure nitric acid was added. The samples were
stored in a cooler before storage in a 4°C refrigerated
room. Analysis of each sample for arsenic concentration
was completed using Environmental Protection Agency
(EPA) method 200.8 with Inductively Coupled Plasma
Mass Spectroscopy (ICP-MS) (Environmental Laboratory
Services, North Syracuse, New York)[27]. The method
limit of detection was 1 μg As/l.
Two 10 ml EDTA tubes were used to collect blood and
were stored in a cooler on ice until processed with cell
lysis solution. Samples were sent to the Molecular Epide-
miology Laboratory at Harvard School of Public Health
for DNA extraction and genotyping.
Genotyping
DNA samples were stored at -80°C. The GSTM1  and
GSTT1  genetic polymorphisms were evaluated using a
previously described multiplex PCR technique[28].
GSTP1 polymorphism was genotyped by the 5' nuclease
assay (TaqMan) using the ABI Prism 7900HT Sequence
Detection System (Applied Biosystems, Foster City, CA).
The primers, probes, and reaction conditions are available
upon request. Genotyping for GSTT1  and  GSTM1  was
completed for 1062 subjects, and genotyping for GSTP1
was completed for 1101 subjects. Laboratory personnel
were blinded to case status, and a random 5% of the sam-
ples were repeated to validate genotyping procedures.
Two authors independently reviewed all results with
100% concordance.
Statistical analysis
Analysis was restricted to subjects who reported using the
same well greater than 6 months to minimize potential
for temporal variability in well arsenic concentration.
Since subjects were frequency matched by age and sex,
these variables were included in all regression mod-
els[29,30]. Arsenic concentration and volume of liquid
consumed per day were not combined as a dose variable,
since liquid volume included juice, milk, soup, tea, and
water. Data exploration using generalized additive models
(GAMs), implemented in R (version 1.8.1), suggested that
the log-odds of case status varied linearly with the arsenic
concentration of well water; consequently untransformed
arsenic concentration was used as a continuous predictor
of case status. The models suggested that the log-odds of
case status had a nonmonotonic relationship with BMI;
therefore a quadratic term for BMI was included. To facil-
itate numerical stability, both linear and quadratic terms
for BMI were centered at the median BMI value, 19.1.
Consolidated categories for educational status and age
were established.
Univariate analyses were performed to describe popula-
tion characteristics and to identify possible data errors
and/or outliers. Continuous variables were summarized
using means, medians, standard deviations and ranges,
while categorical variables were described using percent-
ages. Bivariate analyses (chi-squared tests or t-tests, as
appropriate) were conducted explore differences between
cases and controls prior to multivariate modeling. The fre-
quency distribution of the GSTT1, and GSTM1 polymor-
phisms were tested among controls to ensure Hardy-
Weinberg equilibrium. The heterozygote and homozygote
variant were not combined for GSTP1.
Multiple unconditional logistic regression was used to
evaluate the associations between arsenic exposure in
drinking water on case status. Odds Ratios were obtained
from the regression models, as were their 95% confidence
intervals. Regression models were fit using Statistical
Analysis Systems (SAS Institute Inc, Cary NC) version 8.2.
Two different analyses were done to investigate: 1) the
associations of GST  polymorphisms with skin lesions,
adjusting for well arsenic concentration and 2) the modi-
fication of the relationship between well arsenic concen-
tration and skin lesions by GST polymorphisms. The joint
effects (interaction) of arsenic exposure and each of the
genes were evaluated in additive and multiplicative mod-
els. Categorical variables were created for measures of
arsenic exposure: drinking water arsenic concentration
<50  μg/l and ≥50  μg/l. The deletion polymorphisms
GSTT1  and  GSTM1, were modeled as homozygous
wildtype and heterozygotes compared to homozygote
null.GSTP1 was modeled to determine whether the heter-Environmental Health 2007, 6:5 http://www.ehjournal.net/content/6/1/5
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ozygote variant and the homozygote variant might be
associated with risk of developing skin lesions compared
to wildtype. Variables were created for each combination
of arsenic exposure and genotype, with the reference cate-
gory being low arsenic exposure and either GSTT1 null,
GSTM1 null or GSTP1 wildtype AA. Adjusted ORs and 95%
CIs were evaluated for deviation from the expected null
value on the additive or multiplicative scale. Interaction
Contrast Ratios (ICR) and Bootstrap Percentile Method 1
(BP1) 95% CIs were calculated to quantify departure from
additivity[31]. Synergy on the additive scale is implied by
ICRs greater than zero. ICRs of zero imply no additive
effects on the additive scale. Antagonism on the additive
scale is implied by ICRs less than zero[32]. To estimate
interaction on the multiplicative scale adjusted ORs and
95% CIs were estimated in separate logistic regression
models with interaction terms for each genotype and
arsenic exposure as a continuous variable. Likelihood
ratio tests were conducted comparing adjusted models
with main effects for GSTT1, GSTM1 or GSTP1 and arsenic
exposure and an interaction term compared to the same
model excluding the interaction term.
Sensitivity analysis was conducted by varying weights of
controls selected having a well concentration less than 50
μg/l in a weighted logistic regression analysis as described
previously[33]. Briefly, this method was used to deter-
mine whether the percentage of controls selected from
suspected high and low arsenic areas impacted the stabil-
ity of the ORs of all of the covariates in the regression
models. The weighting varied between 70%–95% of con-
trols with suspected low exposure (<50 μg As/l) and 30%
-5% of controls with suspected high exposure (≥50 μg As/
l). Results can be examined graphically in Figure 1.
Results
Demographic data are presented in Table 1. Of 592 cases,
diffuse melanosis accounted for 31.7% of the cases (n =
377), followed by leukomelanosis (n = 342), spotted
melanosis (n = 145), diffuse keratosis (n = 117), spotted
keratosis (n = 73) and hyperkeratosis (n = 40). Subjects
often had multiple types of lesions. Cases and controls
were not significantly different in terms of age, BMI or
gender. Controls reported using their current well for a
longer duration (p = 0.02), and, conversely, cases reported
a higher frequency of previous well use (p = 0.007). As
expected, cases had significantly higher well arsenic con-
centrations (p < 0.0001). No significant difference in total
liquid consumption was observed. A higher proportion of
cases reported betel nut use (p = 0.007), however there
was no significant difference between cases and controls
in terms of years of betel nut use (p = 0.78) and number
of betel nuts chewed daily (p = 0.53). A higher proportion
of cases reported chewing tobacco use (p < 0.0001), how-
ever there was no difference in years of chewing tobacco
use. Conversely, a higher proportion of controls reported
current cigarette use (p = 0.03) and ever having smoked (p
= 0.0007). Educational status was not significantly differ-
ent between cases and controls. Table 1 shows the geno-
types frequencies for GSTM1  and  GSTT1  and allele
frequencies for GSTP1 among cases and control subjects.
The crude frequencies of the GST SNPs were not signifi-
cantly different between cases and controls.
The main effects for each genotype on skin lesions
adjusted for well arsenic concentration was shown in
Table 2. The GSTT1 wildtype gene carried a higher risk of
skin lesions compared to the null polymorphism (OR =
1.56 (95%CI 1.10–2.19). Compared to the reference cat-
egory GSTP1 AA, the GG genotype had a 86% increase
odds of skin lesions (OR = 1.86 95%CI 1.15–3.00). We
were not able to detect a significant association with
GSTM1  genotype and skin lesions. All models were
adjusted for well As level, L/day of total liquid, previous
well use, age, sex, education, BMI, chewing tobacco, betel
nut use, and smoking status.
Adjusted ORs for the joint effects of well arsenic exposure
and each GST polymorphisms on skin lesions are shown
in Table 3. Reference categories were low arsenic exposure
and GSTM1 null, GSTT1 null or GSTP1 AA, respectively.
When the results were stratified on exposure, individuals
with the GSTT1 wildtype had a higher risk of lesions in the
low (OR = 1.62, 95% CI 1.06–2.49) exposure group as
well as the high exposure group, though the relationship
was not significant at the high arsenic exposure level (OR
= 1.15 95%CI 0.68–1.94). There is little evidence of effect
modification by the GSTM1 genotype. In the low expo-
sure strata, individuals with the GSTP1 GG genotype had
a higher risk of skin lesions (OR = 2.32, 1.31–4.09) than
those individuals with the AA genotype. In the high expo-
sure strata there was no significant effect of the GSTP1
genotype. When the analysis is stratified by genotype for
GSTP1, results were difficult to interpret due to the insuf-
ficient numbers in high exposure and GSTP1 GG category.
Likelihood Ratio Tests (LRT) were not statistically signifi-
cant (GSTT1 0.88, GSTM1 0.96, and GSTP1 0.21).
Interaction Contrast Ratios (ICR)s for the joint effects of
arsenic exposure and the GST polymorphisms are shown
in Tables 3. ICRs were not significant. The results are
imprecise and should be interpreted cautiously.
Results of the sensitivity analysis are described in Figure 1.
The sensitivity analysis of estimates for skin lesion risk
predicted by well arsenic concentration varied with the
weighting of controls selected from suspected high and
low arsenic areas described previously[33]. As expected,
varying the percentage of controls with drinking water As
exposure <50 μg/l did not bias the effect estimates forEnvironmental Health 2007, 6:5 http://www.ehjournal.net/content/6/1/5
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(A) Results from a sensitivity analysis conducted to determine the stability of the main effect of tube well arsenic concentra- tion in 50 ug/L intervals on the odds ratio for developing skin lesions Figure 1
(A) Results from a sensitivity analysis conducted to determine the stability of the main effect of tube well arsenic concentra-
tion in 50 ug/L intervals on the odds ratio for developing skin lesions. (B) Results from a sensitivity analysis conducted to deter-
mine the stability of the main effect of GSTT1 genotype on the odds ratio for developing skin lesions. (C). Results from a 
sensitivity analysis conducted to determine the stability of the main effect of GSTM1 on the odds for developing skin lesions. 
(D) Results from a sensitivity analysis conducted to determine the stability of the main effect of GSTP1 GG allele on the odds for 
developing skin lesions. (E) Results from a sensitivity analysis conducted to determine the stability of the main effect of GSTP1 
AG allele on the odds for developing skin lesions. The sensitivity analysis evaluated the influence of control selection allowing 
for 70–95% of the controls being selected from tube wells containing less than 50 ug/L. The black line represents the sampling 
design employed in this study which assumed that the 80% of the tube wells in Pabna contained arsenic concentrations below 
50 ug/L. As the percentage of controls with arsenic concentrations below 50 ug/L increases, the OR for skin lesions increases 
associated with each 50 μg/l increase in tube well arsenic. The X-axis is the percentage of controls selected from areas sus-
pected to have well water arsenic concentration less than 50 μg/l. Odds ratios and 95% CI are graphed to show the stability of 
the effect estimates as the percentage of controls from low exposure areas are varied in the logistic regression model.Environmental Health 2007, 6:5 http://www.ehjournal.net/content/6/1/5
Page 6 of 10
(page number not for citation purposes)
GSTM1, GSTT1, or GSTP1 for risk of skin lesions (Figure
1).
Discussion
We found that GSTT1 wildtype compared to GSTT1 null,
and GSTP1 GG compared to GSTP1 AA were associated
with an increased odds of arsenic related skin lesions.
While the data were suggestive of GST polymorphisms
modifying the effect of arsenic exposure levels in drinking
water on risk of skin lesions, these effects were not statis-
tically significant.
We found that there was an increased risk of skin lesions
among GSTT1 wildtype individuals who produce enzymes
that may be associated with increased reduction of glu-
tathione. Previous research has found GST levels
increased in arsenic exposed mice and this was thought to
be associated with enhanced arsenic efflux by MRP trans-
porters[14]. While there has been no experimental evi-
dence for GSTT1, increased GST activity is associated with
enhanced arsenic efflux by MRP transporters, and it is
hypothesized that transporters may become saturated at
higher exposures. Saturation may result in elevated tissue
accumulation of arsenic and increased risk of disease[14].
Furthermore GSTP1 activity may work synergistically with
MRP transport of inorganic arsenic as a tri-GSH conju-
gate[34].
We report for the first time that the GSTP1 GG genotype
increases the risk of arsenic related skin lesions in a popu-
lation based study. In vitro studies have shown that cells
that express higher levels of GSTP1 activity were less sen-
sitive to arsenic trioxide induced apoptosis, than cells
devoid of GSTP1 activity and expression[35]. GSTP1 has
Table 1: Characteristics of Skin-Lesion Cases and Population-Based Controls in Pabna, Bangladesh
Controls Cases
Diffuse Melanosis n = 377
Leukomelanosis n = 342
Spotted Melanosis n = 145
Diffuse Keratosis n = 117
Spotted Keratosis n = 73
Hyperkeratosis n = 40
Mean Age in yrs (SD) 33.7 (12.6) n = 597 33.9 (12.7) n = 592 P = 0.58
Mean Body Mass Index (kg/m2) (SD) 20.4 (3.1) n = 597 20.1 (3.1) n- = 592 P = 0.70
% Male 60.3% n = 360 60.3% n = 357 P = 0.91
Mean Duration of Present well use(yrs) (SD) 10.1 (9.0) n = 592 8.0 (7.2) n = 592 P = 0.02
% Reported a Previous Well 2.84% n = 17 7.77% n = 45 P < 0.0001
Mean As concentration of current well (μg/l) (SD) 66.2 (149.6) n = 595 232.8 (315.7) n = 592 P < 0.0001
Mean Daily Total Water/Liquid consumption (L) (SD) 3.8 (1.2) n = 595 3.7 (1.1) n = 592 P = 0.84
% Ever used Betel nuts 24.3% n = 145 27.7% n = 164 P = 0.007
Mean Years of Betel nut Use (SD) 10.8 (8.9) n = 143 11.0 (9.5) n = 160 P = 0.78
Mean Number of Betel nuts chewed per day (SD) 5.6 (3.6) n = 158 5.7 (3.8) n = 149 P = 0.53
% Chew tobacco leaves 16.4% n = 587 17.1% n = 590 P < 0.0001
Mean Years of Tobacco leaves chewed (SD) 9.9 (9.1) n = 95 10.9 (9.4) n = 95 P = 1.0
% Smokes Cigarettes Currently 30.5% n = 597 26.7% n = 592 P = 0.03
% Ever Smoked 31.0% n = 597 28.7% n = 592 P = 0.0007
Education Level n = 597 N = 592 P = 0.80
% Illiterate 17.4% n = 104 22.9% n = 136
% Literate (incomplete Primary Education) 23.8% n = 142 29.4% n = 174
%Completed Primary Education 11.7% n = 79 11.8% n = 70
% Completed Middle School Education 31.9% n = 191 23.5% n = 139
%Completed Secondary Education or More 13.6% n = 81 26.0% n = 154
Polymorphims:
GSTT1 P = 0.07
Null 17.9% 18.9% n = 112 16.9% n = 100
Wildtpe 82.1% 81.1% n = 482 83.1% n = 492
GSTM1 P = 0.72
Null 41.1% 41.1% n = 244 41.0% n = 243
Wildtype 58.9% 58.9% n = 350 59.0% n = 349
GSTP1 P = 0.07
AA 53.8% 53.5% n = 313 54.1% n = 318
AG 38.7% 40.3% n = 236 37.1% n = 218
GG 7.5% 6.2% N = 36 8.8% n = 52Environmental Health 2007, 6:5 http://www.ehjournal.net/content/6/1/5
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been shown to increase growth inhibition of arsenic
treated cancer cells and to prevent apoptosis by inhibiting
JNK and p38 kinase activity[36]. Our findings are consist-
ent with this, in that those individuals with the polymor-
phism associated with lower enzyme activity may be more
sensitive to the effects of arsenic. However another in vitro
study noted that cancer cells were most sensitive to arsenic
exposure when GSH was depleted, but that the cellular
level of GST-π  did not affect cellular sensitivity to
arsenic[37]. While GSTO1-1 has been shown to reduce
methylated arsenic intermediates, in vitro studies have
suggested that GSTP1  expression may promote arsenic
methylation in cancer cells [38-41]. Further study is
needed to clarify the role of the GSTP1 Iso105Val poly-
morphism in arsenic metabolism and in the risk of arsenic
related skin lesions.
It has been suggested that GST substrates and glutathione
conjugates have the ability to induce a variety of Phase II
enzymes, so that polymorphisms in GST may influence
other chemical defense mechanisms[12]. The role of the
GSTP1 Isoleucine (105) to Valine (105) polymorphism
remains to be explained [42], as the polymorphism lead-
ing to lower enzyme activity appears to be associated with
higher risk of skin lesions. In contrast, the expression of
glutathione-theta-transferase through GSTT1 wildtype
expression appears to be associated with a higher risk of
disease. The impact of GSTT1, and GSTP1  polymor-
Table 3: Joint effects of GST genotype and drinking water level of arsenic on Case Status
Overall Joint Effects Joint Effects Stratified on 
Exposure
Joint Effects Stratified on 
Genotype
As Level of Well Controls (N) Cases (N) OR (95%CI) p-value ICR 95%CL OR (95%CI) p-value OR (95%CI) p-value
GSTT1
Null low 85 52 1.0 1.0 1.0
Wildtpe low 376 272 1.62 (1.06–2.49) 0.03 1.62 (1.06–2.49) 0.03 1.0
null high 27 48 3.16 (1.71–5.85) 0.0002 1.0 3.16 (1.71–5.85) 0.0002
Wildtpe high 106 222 3.64 (2.31–5.74) <0.0001 1.15 (0.68–1.94) 0.60 2.24 (1.69–2.98) <0.0001
0.94 (-2.08–1.83)
GSTM1
Null low 189 126 1.0 1.0 1.0
Wildtype low 272 198 1.02 (0.74–1.40) 0.91 1.02 (0.74–1.40) 0.91 1.0
Null high 55 117 2.62 (1.77–3.90) <0.0001 1.0 2.62 (1.77–3.90) <0.0001
Wildtype high 78 151 2.24 (1.56–3.22) <0.0001 0.85 (0.57–1.29) 0.85 2.20 (1.57–3.09) <0.0001
1.02 (-2.40–1.57)
GSTP1
AA low 246 180 1.0 1.0 1.0
AG low 184 110 0.81 (0.58–1.14) 0.23 0.81 (0.58–1.14) 0.23 1.0
GG low 26 32 2.32 (1.31–4.09) 0.004 2.32 (1.31–4.09) 0.004 1.0
AA high 67 138 2.27 (1.60–3.22) <0.0001 1.0 2.27 (1.60–3.22) <0.0001
AG high 52 108 2.49 (1.69–3.68) <0.0001 0.85 (-2.13–1.51) 1.10 (0.72–1.69) 0.67 3.06 (2.01–4.66) <0.0001
GG high 10 20 2.38 (1.11–5.13) 0.03 1.68 (-2.15–1.83) 1.04 (0.48–2.31) 0.90 1.03 (0.41–2.55) 0.95
All models adjusted for liters of liquid/day, age, gender, educational status, BMI, chewing tobacco, betel nut use, smoking status, and previous well use
Table 2: Crude and Adjusted Odds Ratios and 95% CIs for Skin Lesions Predicted by GST Polymorphisms.
Drinking Water Arsenic Concentrations
Crude Model 1 Adjusted Model 1
Genotype OR (95% CI) p-value OR (95% CI) p-value
GSTP1
AA 1.0 1.0
AG 0.90 (0.69–1.17) 0.44 0.89 (0.68–1.17) 0.41
GG 1.79 (1.12–2.88) 0.02 1.86 (1.15–3.00) 0.01
GSTT1 null 1.0 1.0
GSTT1 wildtype 1.52 (1.08–2.13) 0.02 1.56 (1.10–2.19) 0.01
GSTM1 null 1.0 1.0
GSTM1 wildtype 1.0 (0.78–1.29) 0.98 0.99 (0.77–1.28) 0.95
Crude Models adjusted for As concentration of well or As concentration of well water. Model 1 adjusted for L/day of water, well As concentration, 
age, gender, education, BMI, chewing tobacco, betel nut use, and smoking statusEnvironmental Health 2007, 6:5 http://www.ehjournal.net/content/6/1/5
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phisms, arsenic exposure and skin lesions and molecular
mechanisms require further study.
Limitations of our study include the possibility of recall
bias with regard to reported Liters of liquid consumed per
day. Moreover, this measure included water as well as
other beverages, resulting in possible exposure misclassi-
fication for that variable. As with all sample analysis there
is a potential for measurement error. However, rigorous
quality control procedures were in place for the analysis of
water, as well as for DNA extraction and genotyping. In a
previous study in West Bengal India, it was reported by
Ghosh et al. that individuals with GSTM1 wildtype had
significantly higher risk of arsenic-induced skin lesions
(Odds Ratio, 1.73; 95% confidence interval, 1.24–2.22)
[43]. This study did not observe an association between
GSTT1 or GSTP1 and skin lesions in an arsenic exposed
population. Frequencies of GST polymorphisms were
similar between the West Bengal study and our results.
Due to a much smaller sample size Ghosh et al may have
had limited power to detect associations with GSTT1 and
GSTP1. Additionally the West Bengal study had only 22
controls and 33 cases who were homozygote null (-/-),
and 156 controls and 211 cases who were (+/-) or (+,+).
They may not have had an adequate sample size to detect
a significant association for GSTT1. For GSTP1, they had
even fewer subjects which would not have allowed the
ability to detect an association. In the Pabna population,
we reported that individuals with the GG genotype (Val/
Val) had a 1.86 increased odds of skin lesions compared
to those individuals with the GSTP1 AA genotype (OR
1.86 (95%CI 1.15–3.00). Ghosh et al reported having 3
cases and 3 controls with the (Val/Val) or GG genotype so
they lacked the power to detect the association[43]. Our
results are at odds with this population, however as with
all studies of single-nucleotide polymorphisms there may
be other polymorphisms that are of importance that are in
linkage disequlibrium and that may be responsible for
some of the observed effects. It has been hypothesized
that GSTP1 activity can compensate for the absence of
GSTM1 activity[44]. Our study in Pabna, Bangladesh was
an ethnically homogenous population of a much larger
sample size than the previous study. Our results were also
limited by sample size when analysis was stratified on
exposure and genotype for case control status for GSTP1
GG due too few subjects in the high exposure category.
However, GSTP1 GG was statistically significant overall
for skin lesions, as well as in the low exposure drinking
water strata. Despite these limitations, significant differ-
ences in risk of skin lesions associated with main effects of
GSTT1 and GSTP1 genotypes.
Conclusion
While we did not detect statistically significant interac-
tions on the multiplicative or additive scale between
arsenic level and GSTT1, GSTM1 and GSTP1 polymor-
phisms, we report that the main effects of GSTT1 wildtype
and GSTP1 GG appear to be associated with increased risk
of skin lesions. A larger sample size would allow a better
investigation of the effect of the GSTP1 polymorphism at
higher arsenic exposure. There was no evidence of effect
modification of GST polymorphisms and arsenic concen-
tration of drinking water on risk of skin lesions. Further
work is required to characterize the potential mechanisms
related to arsenic metabolism and GSTT1 and GSTP1 pol-
ymorphisms.
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